← All trials
NCT03700801
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2018
- Primary completion
- Mar 31, 2019
- Completion date
- Mar 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 130
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Southern Medical UniversityLead sponsor
- Peking UniversityCollaborator
- Guangdong Pharmaceutical UniversityCollaborator
- Shenzhen UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Zunyi Medical CollegeCollaborator
- First People's Hospital, Shunde ChinaCollaborator
- Dongguan Kanghua HospitalCollaborator
- Southern Medical UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.